Umbrella-Topology Glycan Binding Agents for Influenza HA Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for assessing the potential of avian influenza strains like H5N1, H7N7, H9N2, and H2N2 to mutate and infect humans, and there is a need for understanding HA protein characteristics that allow or prevent human infection, as well as developing effective vaccines and therapeutic strategies for influenza.
Innovation Solution
Development of binding agents that specifically target umbrella-topology glycans with high affinity, competing with hemagglutinin for binding, and providing diagnostic and therapeutic reagents, including vaccines, to address the challenge of HA protein variants and their ability to infect humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If binding agents are developed to specifically target umbrella-topology glycans with high affinity, then the ability to differentiate and bind to human HA receptors is improved, but the complexity of identifying and characterizing these binding agents increases
Solution Approach 1:
The patent utilizes parameter changes in glycan topology (from cone to umbrella topology) as the key differentiating feature. By focusing on the three-dimensional structural parameter of glycan conformation rather than chemical composition, the binding agents achieve high specificity for human HA receptors without requiring complex molecular structures themselves.
Solution Approach 2:
The binding agents exhibit local quality by specifically recognizing and binding to the umbrella-topology conformation of glycans at the HA-receptor interface. This localized structural recognition allows the agents to distinguish between human and avian HA receptors based on the specific spatial arrangement of glycans rather than requiring complex overall molecular features.
2Reliability
If binding agents compete with hemagglutinin for binding to glycans, then the ability to block viral attachment is improved, but the need for precise characterization of binding characteristics increases
Solution Approach 1:
The binding agents serve as intermediary molecules that compete with hemagglutinin for glycans. By acting as mediators in the viral attachment process, they provide a measurable blocking effect that can be used to assess HA protein characteristics without requiring direct observation of viral infection events.
Solution Approach 2:
The binding agents perform preliminary blocking action by occupying glycan binding sites before viral attachment can occur. This preliminary competition allows for the characterization of HA binding characteristics in a controlled manner, simplifying the measurement process compared to studying actual viral infection events.
3Measurement precision
If HA polypeptide variants with altered glycosylation are studied to understand human infection potential, then the ability to predict pandemic risk is improved, but the complexity of analyzing glycosylation patterns increases
Solution Approach 1:
The patent simplifies the analysis of HA variants by focusing on parameter changes in glycan topology (cone versus umbrella) rather than analyzing all possible glycosylation patterns. This reduction to key structural parameters enables efficient assessment of human infection potential without requiring comprehensive glycosylation analysis.
Solution Approach 2:
The approach uses local quality by examining specific glycan conformational features at the binding interface rather than analyzing the entire glycosylation pattern of the HA protein. This localized structural analysis significantly reduces complexity while maintaining predictive accuracy for human infection potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding agents effectively bind to HA variants with altered glycosylation, influencing their binding to human receptors, enabling the development of targeted diagnostic and therapeutic approaches to manage influenza infections.
Implementation Method 1
binding agents that bind to sialylated glycans having an umbrella-like topology... binding agents in accordance with the invention bind to umbrella-topology glycans with high affinity and/or specificity... binding agents in accordance with the invention compete with hemagglutinin for binding to glycans on hemagglutinin receptors
Data Source
AI summary
The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.